CSPC’s SYS6090 Shows 40% Response Rate in Early-Stage Liver Cancer Trial
CSPC said SYS6090 showed a 40% response rate among evaluable liver cancer patients in an early-stage trial.
Related stories
BOJ to Sell ETF Holdings at About 0.1% of Market Trading Value
M impact | EQUITY | Oct 30, 2026, 03:03 AM UTC
Nikkei Futures Down 2.6% After BOJ Decision
Nikkei futures were last down 2.6%, largely unmoved by the BOJ decision.
M impact | EQUITY | Oct 30, 2026, 03:03 AM UTC
Asian session market picture: S&P 500 -0.99%, Nasdaq 100 -2.2%; USD/JPY -0.12%, WTI +1.28%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.99 percent, Nasdaq futures is down 2.2 percent, Dow futures is down 0.16 percent and Russell futures is do
M impact | EQUITY | Oct 30, 2026, 03:00 AM UTC
Sarimelati Kencana Attributes Q3 2026 Net Profit Growth to Operating Efficiencies
M impact | EQUITY | Oct 30, 2026, 02:58 AM UTC
South Korea's Kospi Extends Losses, Down 5.3% at 5,622.84
M impact | EQUITY | Oct 30, 2026, 02:57 AM UTC
Nikkei Falls 3% as Technology Shares Slide on AI Concerns
The Nikkei fell 3% as technology shares declined amid concerns about artificial intelligence.
M impact | EQUITY | Oct 30, 2026, 02:50 AM UTC